Jazz Pharmaceuticals wins approval for HSE reimbursement of cannabis-derived drug

The company acquired GW Pharma, the UK biopharma and producer of cannabis-derived Epidiolex, earlier this year

Jazz Pharmaceuticals acquired GW Pharma, a producer of cannabis-derived medicines, in May 2021 in a cash-and-stock deal worth $7.2 billion (€6.3 billion). Picture: Getty

Jazz Pharmaceuticals, the Irish-based pharmaceutical company, has won approval for HSE reimbursement for its cannabinoid pharmaceutical epilepsy treatment, Epidiolex.

Epidiolex is produced by GW Pharmaceuticals, a UK biopharmaceutical that was acquired by Jazz earlier this year in a $7.2 billion cash-and-stock (€6.3 billion) deal. The drug won approval from the US’s Food and Drug Administration in 2018, the first cannabis-derived drug to be cleared for such.

In Ireland, it is now approved for reimbursement when ...